Synthesis, antioxidant activity, and HPLC enantioseparation of aryloxyaminopropanols derived from naphthalen-2-ol

[1] Baker JG, Hill SJ, Summera RJ. Evolution of β-blocker from anti-anginal drugs to ligand-directed signalling. Trends Pharmacol Sci. 2011;32(4):227–234. BakerJG HillSJ SummeraRJ Evolution of β-blocker from anti-anginal drugs to ligand-directed signalling Trends Pharmacol Sci 2011 32 4 227 234 Search in Google Scholar

[2] Tobe SW. β-adrenergic receptor blockers in hypertension. Can J Cardiol. 2014;30(5):S1–S2. TobeSW β-adrenergic receptor blockers in hypertension Can J Cardiol 2014 30 5 S1 S2 Search in Google Scholar

[3] Akbar S, Alorainy MS. The current status of beta blockers’ use in the management of hypertension. Saudi Med J. 2014;35(11):1307–1317. AkbarS AlorainyMS The current status of beta blockers’ use in the management of hypertension Saudi Med J 2014 35 11 1307 1317 Search in Google Scholar

[4] Zicha S, Tsuji Y, Shiroshita-Takeshita A, Nattel S. Beta-blockers as antiarrhythmic agents. In: Kass RS, Clancy CE, eds. Handbook of Experimental Pharmacology Vol. 171. Heidelberg: Springer-Verlag; 2006. ZichaS TsujiY Shiroshita-TakeshitaA NattelS Beta-blockers as antiarrhythmic agents In: KassRS ClancyCE eds. Handbook of Experimental Pharmacology 171 Heidelberg Springer-Verlag 2006 Search in Google Scholar

[5] Cruickshank JM. Beta-blockers and heart failure. Indian Heart J. 2010;62(2):101–110. CruickshankJM Beta-blockers and heart failure Indian Heart J 2010 62 2 101 110 Search in Google Scholar

[6] Tsujimoto T, Kajio H. Beta-blocker use and cardiovascular event risk in patients with heart failure with preserved ejection fiction. Sci Rep. 2018;8:9556. TsujimotoT KajioH Beta-blocker use and cardiovascular event risk in patients with heart failure with preserved ejection fiction Sci Rep 2018 8 9556 Search in Google Scholar

[7] Fumagalli C, Maurizi N, Marchionni N, Fornasari D. β-Blockers: Their new life from hypertension to cancer and migraine. Pharmacol Res. 2020;151:1045287. FumagalliC MauriziN MarchionniN FornasariD β-Blockers: Their new life from hypertension to cancer and migraine Pharmacol Res 2020 151 1045287 Search in Google Scholar

[8] Brogden RN, Heel RC, Speight TM, Avery GS. Metoprolol: a review of its pharmacological properties and therapeutic efficacy in hypertension and angina pectoris. Drugs. 1977;14(5):321–48. BrogdenRN HeelRC SpeightTM AveryGS Metoprolol: a review of its pharmacological properties and therapeutic efficacy in hypertension and angina pectoris Drugs 1977 14 5 321 48 Search in Google Scholar

[9] Kukin ML, Mannino MM, Freudenberger RS, Kalman J, Buchholz-Varley C, Ocampo O. Hemodynamic comparison of twice daily metoprolol tartrate with once daily metoprolol succinate in congestive heart failure. J Am Coll Cardiol. 2000;35(1):45–50. KukinML ManninoMM FreudenbergerRS KalmanJ Buchholz-VarleyC OcampoO Hemodynamic comparison of twice daily metoprolol tartrate with once daily metoprolol succinate in congestive heart failure J Am Coll Cardiol 2000 35 1 45 50 Search in Google Scholar

[10] Fröhlich H, Zhao J, Täger T, Cebola R, Schellberg D, Katus HA, Grundtvig M, Hole T, Atar D, Agewall S, Frankenstein L. Carvedilol compared with metoprolol succinate in the treatment and prognosis of patients with stable chronic heart failure: carvedilol or metoprolol evaluation study. Circ Heart Fail. 2015;8(5):887–896. FröhlichH ZhaoJ TägerT CebolaR SchellbergD KatusHA GrundtvigM HoleT AtarD AgewallS FrankensteinL Carvedilol compared with metoprolol succinate in the treatment and prognosis of patients with stable chronic heart failure: carvedilol or metoprolol evaluation study Circ Heart Fail 2015 8 5 887 896 Search in Google Scholar

[11] Clemente-Moragón A, Martínez-Milla J, Oliver E, Santos A, Flandes J, Fernández I, Rodríguez-González L, Serrano del Castillo Ch, Ioan AM, López-Álvarez M, Gómez-Talavera S, Galán-Arriola C, Fuster V, Pérez-Calvo C, Ibáñez B. Metoprolol in critically ill patients with COVID-19. J Am Coll Cardiol. 2021;78(10):1001–1010. Clemente-MoragónA Martínez-MillaJ OliverE SantosA FlandesJ FernándezI Rodríguez-GonzálezL Serrano del CastilloCh IoanAM López-ÁlvarezM Gómez-TalaveraS Galán-ArriolaC FusterV Pérez-CalvoC IbáñezB Metoprolol in critically ill patients with COVID-19 J Am Coll Cardiol 2021 78 10 1001 1010 Search in Google Scholar

[12] de Groote P, Ennezat PV, Mouquet F. Bisoprolol in the treatment of chronic heart failure. Health Risk Manag. 2007;3(4):431–439. de GrooteP EnnezatPV MouquetF Bisoprolol in the treatment of chronic heart failure Health Risk Manag 2007 3 4 431 439 Search in Google Scholar

[13] Yasui T, Toru Oka T, Shioyama W, Oboshi M, Fujita M. Bisoprolol transdermal patch treatment for patients with atrial fibrillation after noncardiac surgery: A single-center retrospective study of 61 patients. SAGE Open Medicine. 2020;8: 2050312120907817. YasuiT Toru OkaT ShioyamaW OboshiM FujitaM Bisoprolol transdermal patch treatment for patients with atrial fibrillation after noncardiac surgery: A single-center retrospective study of 61 patients SAGE Open Medicine 2020 8 2050312120907817 Search in Google Scholar

[14] Li Y, Jung NY, Yoo JC, Kim Y, Yi GS. Acebutolol, a cardioselective beta blocker, promotes glucose uptake in diabetic model cells by inhibiting JNK-JIP1 interaction. Biomol Ther (Seoul). 2018;26(5):458–463. LiY JungNY YooJC KimY YiGS Acebutolol, a cardioselective beta blocker, promotes glucose uptake in diabetic model cells by inhibiting JNK-JIP1 interaction Biomol Ther (Seoul) 2018 26 5 458 463 Search in Google Scholar

[15] Baderkhan H, Wanhainen A, Stenborg A, Stattin EL, Björck M. Celiprolol treatment in patients with vascular Ehlers-Danlos syndrome. Eur J Vasc Endovasc Surg. 2021;61(2):326–331. BaderkhanH WanhainenA StenborgA StattinEL BjörckM Celiprolol treatment in patients with vascular Ehlers-Danlos syndrome Eur J Vasc Endovasc Surg 2021 61 2 326 331 Search in Google Scholar

[16] Barton AL, Moffet BS, Valdes SO, Miyake C, Kim JJ. Efficacy and safety of high-dose propranolol for the management of infant supraventricular tachyarrythmias. J Pediatr. 2015;166(1):115–118. BartonAL MoffetBS ValdesSO MiyakeC KimJJ Efficacy and safety of high-dose propranolol for the management of infant supraventricular tachyarrythmias J Pediatr 2015 166 1 115 118 Search in Google Scholar

[17] Bolin EH, Lang SM, Tang X, Collins RT. Propranolol versus digoxin in the neonate for supraventricular tachycardia (from the Pediatric Health Information System). Am J Cardiol. 2017;119(10):1605–1610. BolinEH LangSM TangX CollinsRT Propranolol versus digoxin in the neonate for supraventricular tachycardia (from the Pediatric Health Information System) Am J Cardiol 2017 119 10 1605 1610 Search in Google Scholar

[18] Čižmáriková R, Valentová J, Némethy A. Propranolol as chiral agent. In: Propranolol: Medical uses, mechanisms of action and potential adverse effects. New York: Nova Science Publ.; 2015. ČižmárikováR ValentováJ NémethyA Propranolol as chiral agent In: Propranolol: Medical uses, mechanisms of action and potential adverse effects New York Nova Science Publ. 2015 Search in Google Scholar

[19] Čižmáriková R, Chudáčiková S, Valentová J, Némethy A. Synthesis and enantioseparation of derivatives of propranolol. Acta Fac Pharm Univ Comen. 2012;59:5–13. ČižmárikováR ChudáčikováS ValentováJ NémethyA Synthesis and enantioseparation of derivatives of propranolol Acta Fac Pharm Univ Comen 2012 59 5 13 Search in Google Scholar

[20] Čižmáriková R, Habala L, Markuliak M, Valentová J. Survey of pharmacological activity and pharmacokinetics of selected β-adrenergic blockers in regard to their stereochemistry. Appl Sci. 2019;9:625. ČižmárikováR HabalaL MarkuliakM ValentováJ Survey of pharmacological activity and pharmacokinetics of selected β-adrenergic blockers in regard to their stereochemistry Appl Sci 2019 9 625 Search in Google Scholar

[21] Lee SB, Mai XL, Le TAT, Nguyen TNV, Kang JS, Mar W, Kim KH. Determination of nadolol enantiomers in human plasma using a coupled achiral-chiral high-performance liquid chromatography method. Anal Sci Technol. 2020;33(2):59–67. LeeSB MaiXL LeTAT NguyenTNV KangJS MarW KimKH Determination of nadolol enantiomers in human plasma using a coupled achiral-chiral high-performance liquid chromatography method Anal Sci Technol 2020 33 2 59 67 Search in Google Scholar

[22] Ogasawara H, Yoshida A, Fujio N, Konno S, Ishiko S. [Effect of topical levobunolol on retinal, optic nerve head, and choroidal circulation in normal volunteers]. Nippon Ganka Gakkai Zasshi. 1999;103(7):544–550. OgasawaraH YoshidaA FujioN KonnoS IshikoS [Effect of topical levobunolol on retinal, optic nerve head, and choroidal circulation in normal volunteers] Nippon Ganka Gakkai Zasshi 1999 103 7 544 550 Search in Google Scholar

[23] Ishibashi T, Yokoi N, Kinoshita S. Comparison of the effects of topical levobunolol and timolol solution on the human ocular surface. Cornea 2003;22(8):709–715. IshibashiT YokoiN KinoshitaS Comparison of the effects of topical levobunolol and timolol solution on the human ocular surface Cornea 2003 22 8 709 715 Search in Google Scholar

[24] Sponer G, Borbe HO, Muller-Beckmann B, Freud P, Jakob, B. Naftopidil, a new adrenoceptor blocking agent with Ca(2+)-antagonistic properties: interaction with adrenoceptors. J Cardiovasc Pharmacol. 1992;20:1006–1013. SponerG BorbeHO Muller-BeckmannB FreudP JakobB Naftopidil, a new adrenoceptor blocking agent with Ca(2+)-antagonistic properties: interaction with adrenoceptors J Cardiovasc Pharmacol 1992 20 1006 1013 Search in Google Scholar

[25] Kirsten R, Breidert M, Nelson K, Heine A, Rosenkranz S, Erdeg B, Niebch G, Borbe HO, Siebert-Weigel M, Respondek J. Naftopidil inhibits 5-hydroxytryptamine-induced platelet aggregation and 5-hydroxytryptamine uptake in platelets of healthy volunteers. Eur J Clin Pharmacol. 1994;46:271–274. KirstenR BreidertM NelsonK HeineA RosenkranzS ErdegB NiebchG BorbeHO Siebert-WeigelM RespondekJ Naftopidil inhibits 5-hydroxytryptamine-induced platelet aggregation and 5-hydroxytryptamine uptake in platelets of healthy volunteers Eur J Clin Pharmacol 1994 46 271 274 Search in Google Scholar

[26] de Groot AA, Mathy MJ, van Zwieten PA, Peters SLM. Antioxidant activity of nebivolol in the rat aorta. J Cardiovasc Pharmacol. 2004;43(1):148–153. de GrootAA MathyMJ van ZwietenPA PetersSLM Antioxidant activity of nebivolol in the rat aorta J Cardiovasc Pharmacol 2004 43 1 148 153 Search in Google Scholar

[27] Gomes A, Costa D, Lima JL, Fernandes E. Antioxidant activity of β-blockers: an effect mediated by scavenging reactive oxygen and nitrogen species? Bioorg Med Chem. 2006;14(13):4568–4577. GomesA CostaD LimaJL FernandesE Antioxidant activity of β-blockers: an effect mediated by scavenging reactive oxygen and nitrogen species? Bioorg Med Chem 2006 14 13 4568 4577 Search in Google Scholar

[28] Wendi M, Book MD. Carvedilol a nonselective beta blocking agent with antioxidant properties. Heart Failure 2002;8(3):129–191. WendiM BookMD Carvedilol a nonselective beta blocking agent with antioxidant properties Heart Failure 2002 8 3 129 191 Search in Google Scholar

[29] Kalíková K, Martínková M, Schmid MG, Tesařová E. Cellulose tris-(3,5-dimethylphenylcarbamate)-based chiral stationary phase for the enantioseparation of drugs in supercritical fluid chromatography: comparison with HPLC. J Sep Sci. 2018;41:1471–1478. KalíkováK MartínkováM SchmidMG TesařováE Cellulose tris-(3,5-dimethylphenylcarbamate)-based chiral stationary phase for the enantioseparation of drugs in supercritical fluid chromatography: comparison with HPLC J Sep Sci 2018 41 1471 1478 Search in Google Scholar

[30] Li M, Jiang Z, Di X, Song Y. Enantiomeric separation of six beta-adrenergic blockers on Chiralpak IB column and identification of chiral recognition mechanisms by molecular docking technique. Biomed Chromatogr. 2020;34:e4803. LiM JiangZ DiX SongY Enantiomeric separation of six beta-adrenergic blockers on Chiralpak IB column and identification of chiral recognition mechanisms by molecular docking technique Biomed Chromatogr 2020 34 e4803 Search in Google Scholar

[31] Yang Y, Wang Y, Bao Z, Yang Q, Zhang Z, Ren Q. Progress in the enantioseparation of β-blockers by chromatographic methods. Molecules 2021;26(2):468. YangY WangY BaoZ YangQ ZhangZ RenQ Progress in the enantioseparation of β-blockers by chromatographic methods Molecules 2021 26 2 468 Search in Google Scholar

[32] Bruchatá K, Čižmáriková R, Hroboňová K, Lehotay J, Kyselová Z. Syntéza a štúdium enantioseparácie niektorých potenciálnych β-blokátorov aryloxyaminopropanolového typu metódou HPLC s použitím makrocyklických antibiotík ako chirálnych selektorov. Acta Fac Pharm Univ Comen. 2006;53:68–75. BruchatáK ČižmárikováR HroboňováK LehotayJ KyselováZ Syntéza a štúdium enantioseparácie niektorých potenciálnych β-blokátorov aryloxyaminopropanolového typu metódou HPLC s použitím makrocyklických antibiotík ako chirálnych selektorov Acta Fac Pharm Univ Comen 2006 53 68 75 Search in Google Scholar

[33] Pocrnić M, Ansorge M, Dovhunová M, Habinovec I, Tesařová E, Galić N. Chiral separation of beta-blockers by HPLC and determination of bisoprolol enantiomers in surface waters. Arh Hig Rada Toksikol. 2020;71:56–62. PocrnićM AnsorgeM DovhunováM HabinovecI TesařováE GalićN Chiral separation of beta-blockers by HPLC and determination of bisoprolol enantiomers in surface waters Arh Hig Rada Toksikol 2020 71 56 62 Search in Google Scholar

[34] Nazareth C, Pereira S. A review on chiral stationary phases for separation of chiral drugs. eIJPPR 2020;10(3):77–91. NazarethC PereiraS A review on chiral stationary phases for separation of chiral drugs eIJPPR 2020 10 3 77 91 Search in Google Scholar

[35] Srivastava S, Bhandari K, Shankar G, Singh HK, Saxena AK. Synthesis, anorexigenic activity and QSAR of substituted aryloxypropanolamines. Med Chem Res. 2004;3(8–9):631–642. SrivastavaS BhandariK ShankarG SinghHK SaxenaAK Synthesis, anorexigenic activity and QSAR of substituted aryloxypropanolamines Med Chem Res 2004 3 8–9 631 642 Search in Google Scholar

[36] Fagerstroem A, Nilsson M, Isaksson R. New propranolol analogues: Binding and chiral discrimination by cellobiohydrolase Ce17A. Org Biomol Chem. 2006;4(16):3067–3076. FagerstroemA NilssonM IsakssonR New propranolol analogues: Binding and chiral discrimination by cellobiohydrolase Ce17A Org Biomol Chem 2006 4 16 3067 3076 Search in Google Scholar

[37] Re R, Pellegrini N, Proteggente A, Pannala A, Yang M, Rice-Evans C. Antioxidant activity applying an improved ABTS radical cation decolorization assay. Free Rad Biol Med. 1999;26(9):1231–1237. ReR PellegriniN ProteggenteA PannalaA YangM Rice-EvansC Antioxidant activity applying an improved ABTS radical cation decolorization assay Free Rad Biol Med 1999 26 9 1231 1237 Search in Google Scholar

[38] Malík I, Stanzel L, Csöllei J, Čurillová J. The in vitro antioxidant properties of 2-alkoxyphenylcarbamic acid derivatives containing a 4′-(substituted phenyl)piperazin-1′-yl moiety determined by the 2,2′-azinobis(3-ethylbenzothiazoline-6-sulfonic acid) derived radical cation (ABTS^•+) and ferric reducing antioxidant power (FRAP) assays. Indonesian J Pharm. 2017;28(1):1–9. MalíkI StanzelL CsölleiJ ČurillováJ The in vitro antioxidant properties of 2-alkoxyphenylcarbamic acid derivatives containing a 4′-(substituted phenyl)piperazin-1′-yl moiety determined by the 2,2′-azinobis(3-ethylbenzothiazoline-6-sulfonic acid) derived radical cation (ABTS^•+) and ferric reducing antioxidant power (FRAP) assays Indonesian J Pharm 2017 28 1 1 9 Search in Google Scholar

[39] Čižmáriková R, Markuliak M, Habala L, Valentová J, Bilková A. Synthesis, antimicrobial and antiradical activity of (3-alkoxymethyl-4-hydroxyphenyl)propan-1-ones intermediates of biologically active compounds and activity comparison with 3-(alkoxymethyl)-4-(alkylamino-2-hydroxypropoxyphenyl) alkanones type of beta-blockers. Eur J Pharm Sci. 2020;67:34–44. ČižmárikováR MarkuliakM HabalaL ValentováJ BilkováA Synthesis, antimicrobial and antiradical activity of (3-alkoxymethyl-4-hydroxyphenyl)propan-1-ones intermediates of biologically active compounds and activity comparison with 3-(alkoxymethyl)-4-(alkylamino-2-hydroxypropoxyphenyl) alkanones type of beta-blockers Eur J Pharm Sci 2020 67 34 44 Search in Google Scholar

[40] Čižmáriková R, Valentová J, Habala L, Konušová L. Synthesis, antioxidative activity and enantioseparation of aryloxyaminopropanols derived from 3-methylphenol – bevantolol, toliprolol and a pyrazolidine derivative (in slovak) Farm Obzor 2021;8–9:137–143. ČižmárikováR ValentováJ HabalaL KonušováL Synthesis, antioxidative activity and enantioseparation of aryloxyaminopropanols derived from 3-methylphenol – bevantolol, toliprolol and a pyrazolidine derivative (in slovak) Farm Obzor 2021 8–9 137 143 Search in Google Scholar